Jiménez-Sánchez, Daniel
López-Janeiro, Álvaro http://orcid.org/0000-0002-5744-3115
Villalba-Esparza, María
Ariz, Mikel http://orcid.org/0000-0002-7328-1582
Kadioglu, Ece
Masetto, Ivan
Goubert, Virginie
Lozano, Maria D.
Melero, Ignacio
Hardisson, David http://orcid.org/0000-0002-2183-3699
Ortiz-de-Solórzano, Carlos http://orcid.org/0000-0001-8720-0205
de Andrea, Carlos E. http://orcid.org/0000-0002-7628-8050
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/01723 and PI21/00920)
Article History
Received: 5 August 2022
Accepted: 10 March 2023
First Online: 23 March 2023
Competing interests
: C.E.A. has received research support from AstraZeneca. I.M. has received research support from AstraZeneca, Bristol Myers Squibb, Bioncotech Therapeutics, Alligator Bioscience, Pfizer, Leadartis, and Roche. I.M. is a consultant or advisory board member for AstraZeneca, Roche, Genmab, and Merck Serono. Iv.M. and V.G. are employed by Akoya Biosciences. E.K. is employed by Lunaphore Technologies. The remaining authors declare no competing interests.